supported by the grant from the National"973"Basic Research Program of China(No.2009CB521703);Medical Oncology Leadership of Beijing Municipal Government Health Burean(No.2009-2-16)
Objective: Although the development of trastuzumab has improved the outlook for women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the resistance to anti-HER2 therapy is a growing cl...